CATALYST PHARMACEUTICALS, INC.
CPRXNasdaq
$31.49
↑ +0.0%Jul 14 close · end-of-day
Price
1Y↑ +45.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
No screener snapshot for this ticker.
Company profile
Catalyst Pharmaceuticals, Inc. focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS) and Ruzurgi.
- CEO
- Patrick J. McEnany
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 80
- Headquarters
- Florida
- Website
- catalystpharma.com
Management & directors
- Andrews William T.Chief Medical Officer
- Daly Richard JPresident and CEO
- Del Carmen JeffreyChief Commercial Officer
- Elsbernd BrianChief Compliance/Legal Officer
- Kalb Michael WayneExecutive Vice President & CFO
- Miller SteveChief Op. & Scientific Officer
- Russo GreggChief HR Officer
- Sundaram PreethiChief Strategy Officer
Roles derived from SEC Form 4 filings.
Earnings
CPRX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$149.4M↑ +5.6%
Diluted EPS$0.50↑ +11.1%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $119.1M | $140.8M | $214.2M | $398.2M | $491.7M | $589.0M |
| Gross profit | — | — | — | — | — | — |
| Operating income | $41.3M | $52.4M | $101.8M | $86.8M | $195.1M | $257.8M |
| Net income | $75.0M | $39.5M | $83.1M | $71.4M | $163.9M | $214.3M |
| Diluted EPS | $0.71 | $0.37 | $0.75 | $0.63 | $1.31 | $1.68 |
| Operating cash flow | $45.0M | $60.4M | $116.0M | $143.6M | $239.8M | $208.7M |
| Free cash flow | $45.0M | $59.4M | $116.0M | $143.4M | $239.3M | $208.6M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | 34.7% | 37.2% | 47.5% | 21.8% | 39.7% | 43.8% |
| Net margin | 63.0% | 28.0% | 38.8% | 17.9% | 33.3% | 36.4% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $122.7M | $128.7M | $141.8M | $141.4M | $146.6M | $148.4M | $152.6M | $149.4M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $54.2M | $50.9M | $62.8M | $63.4M | $66.3M | $66.3M | $61.8M | $73.2M |
| Net income | $40.8M | $43.9M | $55.9M | $56.7M | $52.1M | $52.8M | $52.7M | $63.7M |
| Diluted EPS | $0.33 | $0.35 | $0.44 | $0.45 | $0.41 | $0.42 | $0.40 | $0.50 |
| Operating cash flow | $64.1M | $72.9M | $70.9M | $60.0M | $71.3M | $32.4M | $44.9M | $59.6M |
| Free cash flow | $64.1M | $72.6M | $70.8M | $60.0M | $71.3M | $32.4M | $44.9M | $59.6M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | 44.2% | 39.6% | 44.3% | 44.8% | 45.2% | 44.7% | 40.5% | 49.0% |
| Net margin | 33.2% | 34.1% | 39.4% | 40.1% | 35.6% | 35.6% | 34.5% | 42.7% |
Company news
Jul 16, 2026
Jul 10, 2026
- 9d agoWhy Solaris Energy Infrastructure (SEI) Stock Is Up Todayfinance.yahoo.com
- 10d agoSector Update: Energy Stocks Advance Pre-Bell Fridayfinance.yahoo.com
- 10d agoCatalyst Pharmaceuticals Stockholders Clear Angelini Pharma Mergermarketbeat.com
- 10d agoSEI Stock Jumps 5% After-Hours As S&P 600 Inclusion Sparks Buyingstocktwits.com
Jul 2, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-15 | MCENANY PATRICK J | D | 4,171,559 | $31.50 | $131.4M | filing |
| 2026-07-15 | Miller Steve· Chief Op. & Scientific Officer | D | 1,093,803 | $31.50 | $34.5M | filing |
| 2026-07-15 | DENKHAUS DONALD A | D | 498,773 | $31.50 | $15.7M | filing |
| 2026-07-15 | Tierney David S | D | 383,314 | $31.50 | $12.1M | filing |
| 2026-07-15 | Daly Richard J· President and CEO | D | 271,266 | $31.50 | $8.5M | filing |
| 2026-07-15 | Elsbernd Brian· Chief Legal Officer | D | 242,501 | $31.50 | $7.6M | filing |
| 2026-07-15 | Sundaram Preethi· Chief Strategy Officer | D | 54,804 | $31.50 | $1.7M | filing |
| 2026-07-15 | Del Carmen Jeffrey· Chief Commercial Officer | D | 14,337 | $31.50 | $451,615.50 | filing |
| 2026-07-15 | Kalb Michael Wayne· Chief Financial Officer | D | 13,665 | $31.50 | $430,447.50 | filing |
| 2026-07-15 | Thompson Tamar | D | 3,773 | $31.50 | $118,849.50 | filing |
| 2026-07-15 | Harper Molly | D | 3,694 | $31.50 | $116,361.00 | filing |
| 2026-07-15 | Andrews William T.· Chief Medical Officer | D | 2,309 | $31.50 | $72,733.50 | filing |
| 2026-07-15 | Russo Gregg· Chief HR Officer | D | 476 | $31.50 | $14,994.00 | filing |
| 2026-06-03 | Andrews William T.· Chief Medical Officer | Option exercise | 3,052 | — | — | filing |
| 2026-06-03 | Andrews William T.· Chief Medical Officer | Tax withholding | 743 | — | — | filing |
| 2026-02-17 | Russo Gregg· Chief HR Officer | Option exercise | 687 | — | — | filing |
| 2026-02-17 | Russo Gregg· Chief HR Officer | Tax withholding | 211 | — | — | filing |
| 2026-01-05 | Kalb Michael Wayne· Executive Vice President & CFO | Option exercise | 7,139 | — | — | filing |
| 2026-01-05 | Kalb Michael Wayne· Executive Vice President & CFO | Tax withholding | 2,080 | — | — | filing |
| 2026-01-05 | Daly Richard J· President and CEO | Option exercise | 42,105 | — | — | filing |
| 2026-01-05 | Daly Richard J· President and CEO | Tax withholding | 10,577 | — | — | filing |
| 2025-12-29 | DENKHAUS DONALD A | Option exercise | 1,334 | — | — | filing |
| 2025-12-29 | Elsbernd Brian· Chief Compliance/Legal Officer | Option exercise | 6,667 | — | — | filing |
| 2025-12-29 | Elsbernd Brian· Chief Compliance/Legal Officer | Tax withholding | 2,623 | — | — | filing |
| 2025-12-29 | Tierney David S | Option exercise | 1,334 | — | — | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.